New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOxytocin vs PT-141 (Bremelanotide)

Oxytocin vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementSexual Health & Libido
Oxytocin
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
2–3 hours
Admin Route
Intranasal, SubQ, IV
SubQ
Research
Typical Dose
20–40 IU
0.5–1.75 mg
Frequency
As needed (not daily long-term)
As needed (not daily)
Key Benefits
  • Enhances social bonding and trust
  • Reduces social anxiety and fear of rejection
  • Improves autism spectrum symptoms (social cognition)
  • Reduces cortisol and stress reactivity
  • Enhances sexual arousal and intimacy
  • Promotes maternal behavior and bonding
  • May improve depressive symptoms
  • Appetite suppression and metabolic effects
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Mild uterine cramping (avoid in pregnancy)
  • Nasal irritation (intranasal)
  • Headache
  • Potential emotional over-attachment or jealousy amplification
  • +2 more
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With